These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21931017)

  • 1. Survival benefit from up-front fluorouracil, leucovorin, and irinotecan/cetuximab in metastatic colorectal cancer: is it just a now-or-never result?
    Rother MJ
    J Clin Oncol; 2011 Nov; 29(31):4207; author reply 4207-8. PubMed ID: 21931017
    [No Abstract]   [Full Text] [Related]  

  • 2. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
    J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
    Saltz L; Badarinath S; Dakhil S; Bienvenu B; Harker WG; Birchfield G; Tokaz LK; Barrera D; Conkling PR; O'Rourke MA; Richards DA; Reidy D; Solit D; Vakiani E; Capanu M; Scales A; Zhan F; Boehm KA; Asmar L; Cohn A
    Clin Colorectal Cancer; 2012 Jun; 11(2):101-11. PubMed ID: 22055112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab for metastatic colorectal cancer.
    Spiro H
    N Engl J Med; 2009 Jul; 361(1):95; author reply 96-7. PubMed ID: 19571293
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
    Gebbia V; Del Prete S; Borsellino N; Ferraù F; Tralongo P; Verderame F; Leonardi V; Capasso E; Maiello E; Bordonaro R; Stinco S; Agostara B; Barone C
    Clin Colorectal Cancer; 2006 Mar; 5(6):422-8. PubMed ID: 16635281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
    Tabernero J; Van Cutsem E; Díaz-Rubio E; Cervantes A; Humblet Y; André T; Van Laethem JL; Soulié P; Casado E; Verslype C; Valera JS; Tortora G; Ciardiello F; Kisker O; de Gramont A
    J Clin Oncol; 2007 Nov; 25(33):5225-32. PubMed ID: 18024868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERBITUX as a single agent and in combination in colorectal carcinoma.
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):242. PubMed ID: 12113039
    [No Abstract]   [Full Text] [Related]  

  • 12. Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.
    Láng I; Köhne CH; Folprecht G; Rougier P; Curran D; Hitre E; Sartorius U; Griebsch I; Van Cutsem E
    Eur J Cancer; 2013 Jan; 49(2):439-48. PubMed ID: 23116683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
    Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Transition of chemotherapy for metastatic colorectal cancer and recent advances].
    Muro K
    Nihon Rinsho; 2010 Jun; 68(6):1143-9. PubMed ID: 20535969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
    Graziano F; Ruzzo A; Loupakis F; Canestrari E; Santini D; Catalano V; Bisonni R; Torresi U; Floriani I; Schiavon G; Andreoni F; Maltese P; Rulli E; Humar B; Falcone A; Giustini L; Tonini G; Fontana A; Masi G; Magnani M
    J Clin Oncol; 2008 Mar; 26(9):1427-34. PubMed ID: 18349392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the evolution of systemic chemotherapy in the management of colorectal cancer.
    Gustavsson B; Carlsson G; Machover D; Petrelli N; Roth A; Schmoll HJ; Tveit KM; Gibson F
    Clin Colorectal Cancer; 2015 Mar; 14(1):1-10. PubMed ID: 25579803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer].
    Cui F; Chen JZ; Wan C; Chen B; Luo RC; Zheng H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Jul; 12(4):374-7. PubMed ID: 19598023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.
    Cohen MS; Al-Kasspooles MF; Williamson SK; Henry D; Broward M; Roby KF
    Ann Surg Oncol; 2010 Jan; 17(1):296-303. PubMed ID: 19707832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.